Novartis delivered strong sales growth with core margin expansion, built leading advanced therapy platforms and focused the company in 2018

  • Full year net sales up 5% (cc[1], +6% USD) driven by strong performance of growth drivers:
    • Pharmaceuticals BU grew 7% (cc) driven by Cosentyx USD 2.8 billion (+36% cc) and Entresto USD 1.0 billion (+102% cc)
    • Oncology BU grew 9% (cc) driven by AAA[2] (USD 0.4 billion) including Lutathera, Promacta/Revolade USD 1.2 billion (+35% cc) and Tafinlar + Mekinist USD 1.2 billion (+31% cc)
  • Full year core[1] operating income grew 8% mainly driven by higher sales and gross margin expansion
  • Net income was USD …
/by